{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:transferrin aldifitox [INN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT04562766: Phase 3 Interventional Active, not recruiting Immune Thrombocytopenia
(2020)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT01528241: Phase 1 Interventional Completed Depression
(2008)
Source URL:
Class:
MIXTURE
ABP-688 C-11 (8 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enoneO-11C-methyl-oxime), a noncompetitive and highly selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5). It is a promising PET ligand for the quantification of mGlu5 receptors in humans and animals. It readily crosses the blood-brain barrier. The temporal and spatial changes in mGluR5 availability suggest ABP-688 C-11 PET imaging in epilepsy provide abnormal glutamatergic network during epileptogenesis. ABP-688 C-11 was used in receptors imaging in Major Depressive disorder, chronic neuropathic pain, anxiety and other brain disease investigations.
Status:
Investigational
Source:
USAN:PAFLUFOCON D-HEM-IBERFILCON A [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
USAN:PETRAFOCON A-HEM-LARAFILCON A [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
USAN:PLECTRANTHUS AMBOINICUS EXTRACT [USAN]
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT01941966: Phase 2 Interventional Completed Anal Canal Cancer.
(2010)
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
NCT00868166: Phase 3 Interventional Completed Amyotrophic Lateral Sclerosis
(2009)
Source URL:
Class:
MIXTURE
Class:
MIXTURE
Metazocine is a synthetic opioid analgesic with reinforcing properties and PCP-like activity. Metazocine is a Schedule II controlled substance. Metazocine acts as a ligand at opioid, sigma and NMDA receptors. Metazocine enantiomers exert different pharmacological activity.
Status:
Investigational
Class:
MIXTURE